Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders
NCT ID: NCT04231487
Last Updated: 2022-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
210 participants
OBSERVATIONAL
2019-06-27
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A. Objectives
1. Estimate symptom severity of Essential tremor (ET), Parkinson's disease (PD), Huntington's disease (HD), Primary focal dystonia (PFD), spinocerebellar ataxia (SCA), and Functional movement disorders (FMD) using a smartphone-based application
2. Differentiate individuals with the different movement disorders from healthy controls based on features from the smartphone data
3. Differentiate individuals with a specific movement disorder from people with other movement disorders based on features from the smartphone data
B. Hypotheses / Research Question(s) We hypothesize that we can estimate the severity of symptoms using a smartphone application and that, using those estimates, we can differentiate individuals with movement disorders from healthy controls and from people with other movement disorders.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders
NCT03638479
Monitoring Movement Disorder Symptoms With a Mobile Medical App on Off-the-shelf Consumer Mobile Devices
NCT05680961
Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson Disease
NCT01648803
Movement Disorder Quantification Algorithm Development
NCT01534650
Capturing Parkinson's Disease Medication Side Effects During Daily Activities
NCT01429207
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Essential tremor
This is not an intervention study.
Specific to group: a) Diagnosis of ET, b) stable dose of medication for 30 days
No interventions assigned to this group
Parkinson's Disease
This is not an intervention study.
Specific to group: a) Diagnosis of PD, b) stable dose of medication for 30 days
No interventions assigned to this group
Huntington's Disease
This is not an intervention study.
Specific to group: a) Diagnosis of HD, b) stable dose of medication for 30 days
No interventions assigned to this group
Primary Focal Dystonia
This is not an intervention study.
Specific to group: a) Diagnosis of PFD, b) stable dose of medication for 30 days
No interventions assigned to this group
Spinocerebellar Ataxia
This is not an intervention study. Specific to group: a) Diagnosis of SCA, b) stable dose of medication for 30 days
No interventions assigned to this group
Functional Movement Disorder
This is not an intervention study. Specific to group: a) Diagnosis of FMD, b) stable dose of medication for 30 days
No interventions assigned to this group
Healthy Controls
This is not an intervention study.
People with Healthy Controls
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* Ambulatory
* English speaking
* Specific to group 1: a) Diagnosis of ET, b) stable dose of medication for 30 days
* Specific to group 3: a) Diagnosis of PD, b) stable dose of medication for 30 days
* Specific to group 4: a) Diagnosis of HD, b) stable dose of medication for 30 days
* Specific to group 5: a) Diagnosis of PFD, b) stable dose of medication for 30 days
* Specific to group 6: a) Diagnosis of SCA, b) stable dose of medication for 30 days
* Specific to group 7: a) Diagnosis of FMD, b) stable dose of medication for 30 days
Exclusion Criteria
* Inability to understand task or protocol due to cognitive problems
* Other neurological condition that could affect the performance of motor tasks
* Musculoskeletal condition that could affect the performance of motor tasks
* Uncorrected vision impairment
* Specific to groups 1, 3, 4, 5, 6, and 7: Expected change in medication within the next 8 weeks
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rutgers, The State University of New Jersey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jean-Francois Daneault, Ph.D.
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rutgers University
Newark, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro2018002015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.